Search for "histidine" in Full Text gives 69 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2016, 12, 97–109, doi:10.3762/bjoc.12.11
Graphical Abstract
Figure 1: Example of elucidation of 2D NMR spectra of 2-O-Cin-α-CD.
Figure 2: 2D ROESY spectrum of 2-O-Cin-α-CD in D2O at 25 °C at 24 mM concentration.
Figure 3: Expansion of the 2D ROESY spectrum of 2-O-Cin-α-CD indicating the geometric arrangement.
Figure 4: 1H NMR spectra of 2-O-Cin-α-CD in D2O at 25 °C at different concentrations.
Figure 5: 1H NMR spectra of 3-O-Cin-α-CD in D2O at 25 °C recorded at various concentrations.
Figure 6: Diffusion coefficients of 2-O-Cin-α-CD (black) and, 3-O-Cin-α-CD (red) in D2O at various concentrat...
Figure 7: Effect of solvent on the size distribution of aggregates formed by 2-O-Cin-α-CD at 25 °C (the appli...
Figure 8: Effect of a solvent on the size distribution of aggregates formed by 3-O-Cin-α-CD at 25 °C (the app...
Figure 9: Aggregate sizes (diameter) of 2-O-Cin-α-CD (black) and 3-O-Cin-α-CD (red) in water at various tempe...
Figure 10: Schematic representation of the DLS experiment proving the host–guest nature of the aggregate forma...
Figure 11: The effect of competitive additives on the size distribution of aggregates formed by 3-O-Cin-α-CD a...
Figure 12: Expansion of the 2D ROESY spectrum of 2-O-Cin-α-CD in the presence of CioOK as competitive guest mo...
Figure 13: 1H NMR spectrum of 2-O-Cin-α-CD before (up) and after (down) the addition of CioOK in 5-fold molar ...
Figure 14: The influence of 5 mM 2-O-Cin-α-CD in BGE (right column) on the decrease of the effective electroph...
Beilstein J. Org. Chem. 2015, 11, 2334–2342, doi:10.3762/bjoc.11.254
Graphical Abstract
Figure 1: Three new bromotyrosine derivatives isolated from sponge Aplysina lacunosa: 14-debromo-11-deoxyfist...
Figure 2: Bromotyrosine alkaloids and brominated compounds isolated from the sponge Aplysina lacunosa.
Figure 3: 1,1-ADEQUATE spectrum of 14-debromo-11-deoxyfistularin-3 (1).
Figure 4: The tissue damage induced chemical conversion from fistularin-3 (5) to 19 by an undefined enzyme in...
Figure 5: Diacetylhexadellin B (20) isolated from sponge Hexadella sp.
Figure 6: Bromotyrosine alkaloid (21) isolated from the sponge Verongula sp.
Beilstein J. Org. Chem. 2015, 11, 1713–1720, doi:10.3762/bjoc.11.186
Graphical Abstract
Figure 1: Library generation of P450cam[Tyr96Phe]-RhFRed. Active site of the P450cam-RhFRed variant Tyr96Phe ...
Figure 2: Radar plots illustrating the substrate acceptance of P450cam-RhFRed variants from library I. Colour...
Figure 3: Yields of alcohols (R,S)-9-11 (grey bars) and ketone products 13–15 (blue bars) in sub-pools of lib...
Beilstein J. Org. Chem. 2015, 11, 848–849, doi:10.3762/bjoc.11.94
Figure 1: Multivalent interactions shift the equilibrium and enhance the binding strength. Reprinted with per...
Beilstein J. Org. Chem. 2015, 11, 763–772, doi:10.3762/bjoc.11.86
Graphical Abstract
Scheme 1: Synthesis of multivalent arginine and histidine functionalized dPG-NH2 50%. The depicted dPG-NH2 re...
Figure 1: Agarose gel electrophoresis retardation assay of AAdPGs/siRNA polyplexes. (A) dPG-13Arg13His, (B) d...
Figure 2: Size measurements of dPG-NH2 50% and AAdPGs/siRNA complexes. Intensity distributions of all polyple...
Figure 3: The result of MTT assay on a NIH 3T3 cell line transfected with AAdPG, dPG-NH2 50%, and 90%/siRNA p...
Figure 4: Cell viability versus transfection efficiency of dPG-8Arg30His and dPG-NH2 90% at N/P ratio 30.
Figure 5: Summary of transfection results versus viability of AAdPGs with various Arg and His composition rat...
Figure 6: Confocal images of NIH 3T3 cells treated with Cy3-siRNA/vector complexes: (A) naked siRNA, (B) lipo...
Beilstein J. Org. Chem. 2015, 11, 74–84, doi:10.3762/bjoc.11.11
Graphical Abstract
Figure 1: Typical OSK rod A with solubility enhancing sleeve (D) and building blocks B,C,E.
Figure 2: Fundamental structure of articulated rods (blue = legs, red = joint, green = terminal functionaliti...
Figure 3: Synthetic strategy towards articulated rods.
Scheme 1: Synthesis of building block 8 (i: trimethylsilylpropargyl-4-nitrophenylcarbonate. ii: Dess–Martin-p...
Scheme 2: Synthesis of articulated rod 11 (i: CBr4, PPh3, NaN3. ii: K2CO3/MeOH. iii: Cu/C DCM/MeOH 1:1, cat. ...
Scheme 3: Sequential deprotection of 11 and synthesis of triple articulated rod 14 (i: K2CO3/MeOH. ii: CBr4/P...
Scheme 4: Synthesis of articulated rods 23–25 with increased solubility (i: 4-hydroxypiperidine, DCC, HOBt. i...
Scheme 5: Macrocyclization of articulated rod 25.
Scheme 6: Synthesis of building blocks 27–29 (i: 1. pyrene-1-ylacetic acid, DCC/DMAP, 68%; 2. Dess–Martin per...
Scheme 7: Synthesis of articulated rods 32a–c (i: NaH, TMSCl, TMSOTf. ii: Cu/C, Et3N).
Scheme 8: Synthesis of articulated rods 33, 34 and 36.
Scheme 9: Synthesis of articulated rod 39 (i: cinnamoyl chloride, DMAP, pyridine. ii: DMF 120 °C).
Scheme 10: Synthesis of functionalized articulated rod 43 (i: PYBOP, Et3N. ii: KOH, H2O. iii: 32c, quant.).
Scheme 11: Stretched-folded equilibrium of pyrene labelled AR 32a.
Figure 4: Fluorescence spectra of AR 32a in EPA at different temperatures (c = 5·10−6 mol/L).
Figure 5: Monomer–excimer ratio IM/IEX of the fluorescence of 32a depending on solvent viscosity (DCE = 1,2-d...
Figure 6: Monomer–excimer ratio IM/IEX of the fluorescence of 32a depending on the addition of cyclodextrines...
Scheme 12: Formation of pseudorotaxanes from AR 32a and cyclodextrines.
Figure 7: Influence of Triton X-100 on the fluorescence spectra of 32a in aqueous solution. 32a was added fro...
Figure 8: Comparison of photochemical reactivity of 32b, 33a, 39 (left). Irradiation UV spectrum of 32b in AC...
Beilstein J. Org. Chem. 2014, 10, 2836–2843, doi:10.3762/bjoc.10.301
Graphical Abstract
Figure 1: Aggregate size analysis of aqueous solutions of G8 and ibuprofen by PCS. a) G8 in 1% solution; b) s...
Scheme 1: Schematic representation of the preparation of HP-substituted maltooligomers.
Figure 2: Electropherograms of tested model drugs in the presence of 2-hydroxypropylated acyclic and cyclic d...
Beilstein J. Org. Chem. 2014, 10, 2566–2572, doi:10.3762/bjoc.10.268
Graphical Abstract
Figure 1: Amino acid functionalized nucleosides.
Scheme 1: Reagents and conditions: a) i. Et3N, Pd(PPh3)4, THF, CO (4 bar), 70 °C, 48 h, ii. Et3N, di-tert-but...
Scheme 2: Reagents and conditions: a) Et3N, Pd(PPh3)4, THF, CO (4 bar), 48 h, 70 °C (68%); b) Et3N·3HF, Et3N,...
Scheme 3: Reagents and conditions: a) Et3N, Pd(PPh3)4, THF, CO (4 bar), 48 h, 70 °C (90%); b) Et3N·3HF, Et3N,...
Beilstein J. Org. Chem. 2014, 10, 2448–2452, doi:10.3762/bjoc.10.255
Graphical Abstract
Figure 1: Structures of compounds 1–3.
Scheme 1: Hypothetical one-pot synthesis of compound 4a and/or 4b.
Figure 2: Structure of compound 6 determined by single crystal X-ray diffractometry.
Scheme 2: Evaluation of the substrate scope using RB as oxygen (1O2) sensitizer “on water”.
Scheme 3: Evaluation of the oxidative coupling in the absence of RB, on water.
Beilstein J. Org. Chem. 2014, 10, 1166–1196, doi:10.3762/bjoc.10.117
Graphical Abstract
Scheme 1: Pioneer works of Atherton, Openshaw and Todd reporting on the synthesis of phosphoramidate starting...
Scheme 2: Mechanisms 1 (i) and 2 (ii) suggested by Atherton and Todd in 1945; adapted from [1].
Scheme 3: Two reaction pathways (i and ii) to produce chlorophosphate 2. Charge-transfer complex observed whe...
Scheme 4: Mechanism of the Atherton–Todd reaction with dimethylphosphite according to Roundhill et al. (adapt...
Scheme 5: Synthesis of dialkyl phosphate from dialkyl phosphite (i) and identification of chloro- and bromoph...
Scheme 6: Synthesis of chiral phosphoramidate with trichloromethylphosphonate as the suggested intermediate (...
Scheme 7: Selection of results that address the question of the stereochemistry of the AT reaction (adapted f...
Scheme 8: Synthesis of phenoxy spirophosphorane by the AT reaction (adapted from [34]).
Scheme 9: Suggested mechanism of the Atherton–Todd reaction, (i) and (ii) formation of chlorophosphate with a...
Scheme 10: AT reaction in biphasic conditions (adapted from [38]).
Scheme 11: AT reaction with iodoform as halide source (adapted from [37]).
Scheme 12: AT reaction with phenol at low temperature in the presence of DMAP (adapted from [40]).
Scheme 13: Synthesis of a triphosphate by the AT reaction starting with the preparation of chlorophosphate (ad...
Scheme 14: AT reaction with sulfonamide (adapted from [42]).
Scheme 15: Synthesis of a styrylphosphoramidate starting from the corresponding aniline (adapted from [43]).
Scheme 16: Use of hydrazine as nucleophile in AT reactions (adapted from [48]).
Scheme 17: AT reaction with phenol as a nucleophilic species; synthesis of dioleyl phosphate-substituted couma...
Scheme 18: Synthesis of β-alkynyl-enolphosphate from allenylketone with AT reaction (adapted from [58]).
Scheme 19: Synthesis of pseudohalide phosphate by using AT reaction (adapted from [67]).
Scheme 20: AT reaction with hydrospirophosphorane with insertion of CO2 in the product (adapted from [69]).
Scheme 21: AT reaction with diaryl phosphite (adapted from [70]).
Scheme 22: AT reaction with O-alkyl phosphonite (adapted from [71]).
Scheme 23: Use of phosphinous acid in AT reactions (adapted from [72]).
Scheme 24: AT reaction with secondary phosphinethiooxide (adapted from [76]).
Scheme 25: Use of H-phosphonothioate in the AT reaction (adapted from [78]).
Scheme 26: AT-like reaction with CuI as catalyst and without halide source (adapted from [80]).
Scheme 27: Reduction of phenols after activation as phosphate derivatives (adapted from [81] i ; [82], ii; and [83], iii).
Scheme 28: Synthesis of medium and large-sized nitrogen-containing heterocycles (adapted from [85]).
Scheme 29: Synthesis of arylstannane from aryl phosphate prepared by an AT reaction (adapted from [86]).
Scheme 30: Synthesis and use of aryl dialkyl phosphate for the synthesis of biaryl derivatives (adapted from [89])....
Scheme 31: Synthesis of aryl dialkyl phosphate by an AT reaction from phenol and subsequent rearrangement yiel...
Scheme 32: Selected chiral phosphoramidates used as organocatalyst; i) chiral phosphoramidate used in the pion...
Scheme 33: Determination of ee of H-phosphinate by the application of the AT reaction with a chiral amine (ada...
Scheme 34: Chemical structure of selected flame retardants synthesized by AT reactions; (BDE: polybrominated d...
Scheme 35: Transformation of DOPO (i) and synthesis of polyphosphonate (ii) by the AT reaction (adapted from [117] ...
Scheme 36: Synthesis of lipophosphite (bisoleyl phosphite) and cationic lipophosphoramidate with an AT reactio...
Scheme 37: Use of AT reactions to produce cationic lipids characterized by a trimethylphosphonium, trimethylar...
Scheme 38: Cationic lipid synthesized by the AT reaction illustrating the variation of the structure of the li...
Scheme 39: Helper lipids for nucleic acid delivery synthesized with the AT reaction (adapted from [130]).
Scheme 40: AT reaction used to produce red/ox-sensitive cationic lipids (adapted from [135]).
Scheme 41: Alkyne and azide-functionalized phosphoramidate synthesized by AT reactions,(i); illustration of so...
Scheme 42: Cationic lipids exhibiting bactericidal action – arrows indicate the bond formed by the AT reaction...
Scheme 43: β-Cyclodextrin-based lipophosphoramidates (adapted from [138]).
Scheme 44: Polyphosphate functionalized by an AT reaction (adapted from [139]).
Scheme 45: Synthesis of zwitterionic phosphocholine-bound chitosan (adapted from [142]).
Scheme 46: Synthesis of AZT-based prodrug via an AT reaction (adapted from [143]).
Beilstein J. Org. Chem. 2013, 9, 2022–2027, doi:10.3762/bjoc.9.238
Graphical Abstract
Scheme 1: Batch synthesis of NBDM. a) NaNO2, Amberlite IR-120 H+ (100 mL), 0 °C, water, 4 h. b) NH2OH·HCl, Na...
Scheme 2: The initial polymer-supported nitrite set up. A solution of glucosamine hydrochloride was passed ov...
Scheme 3: Continuous flow synthesis of the key intermediate 1-amino-2,5-anhydro-D-mannose (3).
Figure 1: Normalized NBDM absorption and emission, 40 µM and 2 µM.
Figure 2: NBDM fluorescence from 1–40 µM (PBS buffer). The data set was plotted in OriginPro 8.6 and fitted u...
Figure 3: Comparison of quenching 2 µM NBDM, as measured by fluorescence intensity of Trypan Blue, Bromopheno...
Figure 4: Comparison of quenching 2 µM NBDM, as measured by fluorescence intensity of methionine and histidin...
Beilstein J. Org. Chem. 2013, 9, 1352–1382, doi:10.3762/bjoc.9.153
Graphical Abstract
Figure 1: Qualitative orbital diagram for a d8 metal in ML4 square-planar and ML3 T-shaped complexes.
Figure 2: Walsh diagram for the d-block of a d8 ML3 complex upon bending of one L–M–L angle.
Figure 3: Neutral Y-shaped Pt complex Y1 [15]. Angles are given in degrees.
Figure 4: General classification of T-shaped Pt(II) structures according to the fourth coordination site.
Figure 5: Hydride, boryl and borylene true T-shaped Pt(II) complexes.
Figure 6: NHC-based true T-shaped Pt(II) complexes.
Figure 7: Phosphine-based agostic T-shaped Pt(II) complexes. Compounds in brackets correspond with hydrido–al...
Figure 8: Phenylpyridine and NHC-based agostic T-shaped Pt(II) complexes.
Figure 9: Counteranion coordination in T-shaped Pt(II) complexes.
Figure 10: Phosphine-based solvento Pt(II) complexes.
Figure 11: Nitrogen-based solvento Pt(II) complexes.
Figure 12: Pincer-based solvento Pt(II) complexes.
Figure 13: Structure of the QM/MM optimized cisplatin–protein adduct [94].
Figure 14: NMR coupling constants used for the characterization of three-coordinate Pt(II) species.
Figure 15: The chemical formula of the complexes discussed in Table 2.
Scheme 1: Halogen abstraction from 1.
Scheme 2: Halogen abstraction from 2 forming the dicationic complex T3 [22].
Scheme 3: Hydrogenation of complexes A5a and A5b [39].
Scheme 4: Hydrogenation of complexes 3 and A5c [40].
Scheme 5: Intermolecular C–H bond activation from T5a [28].
Scheme 6: Protonation of complexes 4 [35,36].
Scheme 7: Cyclometalation of 5 [43].
Scheme 8: Protonation of 6.
Scheme 9: Reductive elimination of ethane from 7.
Scheme 10: Reductive elimination of methane from six-coordinate Pt(IV) complexes.
Scheme 11: Proposed dissociative mechanism for the fluxional motion of dmphen in [Pt(Me)(dmphen)(PR3)]+ comple...
Figure 16: Feasible interactions for unsaturated intermediates 11b (left) and 12b (right) during fluxional mot...
Scheme 12: Halogen abstraction from 13a,b and subsequent cyclometalation to yield complexes A5a,b [39].
Scheme 13: Proposed mechanism for the acid-catalyzed cyclometalation of 14 via intermediate 15 [41].
Scheme 14: Proposed mechanism for the formation of 19 [102].
Scheme 15: Cyclometalation of 20 via thioether dissociation [117].
Figure 17: Gibbs energy profile (in chloroform solvent) for the cyclometalation of 23 [120].
Scheme 16: Coordination of tmtu to 29 and subsequent C–H bond activation via three-coordinate species 31 and 32...
Scheme 17: Cyclometalation process of NHC-based Pt(II) complexes [28,44].
Scheme 18: Cyclometalation process of complex A9 [43].
Scheme 19: “Rollover” reaction of 38 and subsequent oligomerization [123].
Scheme 20: Proposed mechanism for the formation of cyclometalated species 44 [124].
Scheme 21: Self-assembling process of 45 by “rollover” reaction [126].
Scheme 22: “Rollover” reaction of A9. Energies (solvent) in kcal mol−1 [127].
Scheme 23: Proposed mechanisms for the “rollover” cyclometalation of 52 in gas-phase ion-molecule reactions [128].
Scheme 24: β-H elimination and 1,2-insertion equilibrium involving A1d and the subsequent generation of 57 [35].
Scheme 25: Proposed mechanism for thermolysis of 7b and 7c in benzene-d6 and cyclohexane-d12 solvents [101].
Scheme 26: β-H elimination process of A11a [28].
Scheme 27: Intermolecular C–H bond activation from 62 [95].
Scheme 28: Reductive elimination of methane from 65 followed by CD3CN coordination or C–D bond-activation proc...
Figure 18: DFT-optimized structures describing the κ2 (69, left) and κ3 (69’, right) coordination modes of [Pt...
Scheme 29: Intermolecular arene C–H bond activation from NHC-based complexes [28].
Figure 19: Energy profiles (in benzene solvent) for the benzene C–H bond activation from A11a, A11b, T5a and T...
Scheme 30: Intermolecular arene C–H bond activation from PNP-based complex 71 [12].
Scheme 31: Intermolecular C–H bond-activation by gas-phase ion-molecule reactions of 74 [7,142].
Scheme 32: Dihydrogen activation through complexes A5a, A5b [39], A5c [40] and S1a [54].
Scheme 33: Dihydrogen activation through complexes A7 and 16 [41]. For a: see Scheme 13.
Scheme 34: Br2 and I2 bond activations through complexes A11a and T5a [143].
Scheme 35: Detection and isolation of the Pt(III) complex 81a [143].
Scheme 36: Cl2 bond activation through complexes 82 and 83 [144].
Scheme 37: cis–trans Isomerization mechanism of the solvento Pt(II) complexes S5 [2,61].
Figure 20: Energy profiles for the isomerization of complexes [Pt(R)(PMe3)2(NCMe)]+ where R means Me (85a, red...
Figure 21: DFT-optimized structure of intermediate 86 [62]. Bond distances in angstrom and angles in degrees.
Scheme 38: Proposed dissociative ligand-substitution mechanism of cis-[Pt(R)2S2] complexes (87) [117].
Scheme 39: Proposed mechanisms for the ligand substitution of the dinuclear species 91 [146].
Beilstein J. Org. Chem. 2013, 9, 544–556, doi:10.3762/bjoc.9.60
Graphical Abstract
Figure 1: Design of the biotinylated Hsp90 probes based on PU-H71 (1a).
Scheme 1: Reagents and conditions: (a) D-biotin, DCC, DMAP, CH2Cl2, sonicate; (b) EZ-Link® NHS-LC-Biotin, DIE...
Scheme 2: Reagents and conditions: (a) 6-Boc-aminocaproic acid, DCC, DMAP, CH2Cl2, rt; (b) TFA, CH2Cl2, rt; (...
Figure 2: Analysis of the affinity and selectivity of the biotinylated probes for Hsp90. (a) K562 cancer cell...
Figure 3: Use of probe 2g to detect oncogenic Hsp90 by flow cytometry (a) and (b) and by microscopy (c). For ...
Beilstein J. Org. Chem. 2011, 7, 518–524, doi:10.3762/bjoc.7.60
Graphical Abstract
Scheme 1: Three phthalimide/amino acid model reactions: Norrish II process of 1, PET decarboxylation of 3, PE...
Figure 1: Phthalimides from tyrosine 8, histidine 9 and tryptophan 10.
Scheme 2: PET decarboxylation/photocleavage of 8 and 9.
Figure 2: Structure of the tryptophan derivative 10 in the crystal.
Figure 3: UV–vis absorption spectra of compounds 8–10 (c = 2 × 10−4 in CH3OH).
Scheme 3: Direct, triplet-sensitized and ET-sensitized photochemistry of 10.
Figure 4: Fluorescence spectra of compounds 8–10 (c = 6 × 10−5 in CH3OH).
Scheme 4: Mechanistic scenario.
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2010, 6, 1174–1179, doi:10.3762/bjoc.6.134
Graphical Abstract
Scheme 1: Lipase-catalyzed acetylation of racemic benzylic secondary alcohol [(RS)-4] and its application.
Scheme 2: FeCl3-meditated synthesis of bis-imines.
Scheme 3: Preparation of racemic 3-(1-hydroxyethyl)phenyl ethyl(methyl)carbamate [(RS)-4]
Scheme 4: Proposed reaction mechanism of lipase-catalyzed acetylation of racemic alcohol 4.
Scheme 5: Complete synthesis of rivastigmine.
Beilstein J. Org. Chem. 2010, 6, 973–977, doi:10.3762/bjoc.6.109
Graphical Abstract
Figure 1: Molecular structures of β-Ala-His-EO2-C14 (a) and Gly-Gly-His-EO2-C14 (b).
Figure 2: ATR spectra of β-Ala-His-EO2-C14 in xerogel and D2O hydrogel, respectively.
Figure 3: SAXS profile of concentrated gel of β-Ala-His-EO2-C14 at different temperatures (where S = 2π/q and...
Figure 4: SEM micrographs of β-Ala-His-EO2-C14 hydrogels after drying.
Figure 5: 2D/3D self assembling of β-Ala-His-EO2-C14.
Beilstein J. Org. Chem. 2010, 6, 810–822, doi:10.3762/bjoc.6.91
Graphical Abstract
Figure 1: The photoaffinity technique allows the identification of ligand binding sites of a receptor protein...
Figure 2: a) Three known photolabile α-D-mannosides that differ in the nature of the photoactive functional g...
Scheme 1: Synthesis of photoactive glycoamino acids 11 and 12. i) Fmoc-Asp-OtBu (for 7), Fmoc-Asp(OtBu)-OH (f...
Scheme 2: Photo-crosslinking experiments with the model peptide angiotensin II and the photoactive mannosides ...
Figure 3: Affino dot–blot with FimHtr and photoactive mannosides applied to nitrocellulose disks. It was irra...
Figure 4: MS/MS spectra of angiotensin II (a) and of angiotensin II, photo-crosslinked with diazirine 2 (b), ...
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...